You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
McKinsey
Express Scripts
AstraZeneca
Merck

Last Updated: September 22, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,771,739

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,771,739 protect, and when does it expire?

Patent 8,771,739 protects TOLSURA and is included in one NDA.

This patent has twelve patent family members in seven countries.

Summary for Patent: 8,771,739
Title:Pharmaceutical compositions for poorly soluble drugs
Abstract: The present invention provides a pharmaceutical composition of a practically insoluble drug, wherein the composition may be administered with food or without food. The composition may be in the form of a solid dispersion of the practically insoluble drug and a polymer having acidic functional groups, and the composition may in vitro form a suspension.
Inventor(s): Hayes; David (Rostrevor, AU), Morella; Angelo M. (Athelstone, AU)
Assignee: Mayne Pharma International Pty Ltd (Melbourne, AU)
Application Number:11/763,578
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Compound; Process; Dosage form;

Drugs Protected by US Patent 8,771,739

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Mayne Pharma Intl TOLSURA itraconazole CAPSULE;ORAL 208901-001 Dec 11, 2018 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,771,739

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
AustraliaPQ4854Dec 23, 1999
AustraliaPQ7450May 12, 2000

International Family Members for US Patent 8,771,739

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2331801   Start Trial
Australia 7252900   Start Trial
Australia 782469   Start Trial
Canada 2396380   Start Trial
European Patent Office 1239831   Start Trial
European Patent Office 2415462   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Harvard Business School
McKesson
Colorcon
Baxter
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.